Critically understudied in the era of T cell immunotherapies, aggregation of B cells within
tertiary lymphoid structures (TLS) has recently been linked to improved response and …

Immune checkpoint inhibitors utilize the immune system to kill cancer cells and are now
widely applied across numerous malignancies. Pembrolizumab has two breast-specific …

Immune checkpoints are regulators of immune activation that can be triggered to suppress
the immune response against tumours. Immune checkpoint inhibitors (ICIs) have shown …

Background Hormone receptor (HR)+ breast cancer (BC) is responsible for the majority of
BCs and-related deaths in the US. 1 Standard treatment for local disease involves surgery …

Immune checkpoint inhibitors have modified the treatment algorithm in a variety of cancer
types, including breast cancer. Nevertheless, optimal selection of ideal candidates to these …

Simple Summary Breast cancer (BC) is the most common malignant neoplasm in women
and one of the leading causes of cancer death in women worldwide. Programmed death …

Abstract Purpose of Review Immune checkpoint blockade (ICB) has changed the clinical
course of multiple cancer types and durable responses have now been observed in breast …

Cancer immunotherapy is emerging as the most promising novel strategy for cancer
treatment. Cancer immunotherapy is broadly categorized into three forms: immune …

Immunotherapies blocking the PD-1/PD-L1 checkpoint show some efficacy in metastatic
breast cancer (mBC) but are often hindered by immunosuppressive mechanisms …

Background: The role of immune checkpoint PD-1/PD-L1 inhibitor (ICI) in breast cancer (BC)
is being investigated in clinical trials. Preclinical evidence strongly supports the synergistic …